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In this study, we investigated the signiﬁcance of b2-adrenergic
receptor (b2AR) in age-related impaired insulin secretion and
glucose homeostasis. We characterized the metabolic phenotype
of b2AR-null C57Bl/6N mice (b2AR
2/2) by performing in vivo and
ex vivo experiments. In vitro assays in cultured INS-1E b-cells
were carried out in order to clarify the mechanism by which
b2AR deﬁciency affects glucose metabolism. Adult b2AR
2/2 mice
featured glucose intolerance, and pancreatic islets isolated from
these animals displayed impaired glucose-induced insulin release,
accompanied by reduced expression of peroxisome proliferator–
activated receptor (PPAR)g, pancreatic duodenal homeobox-1
(PDX-1), and GLUT2. Adenovirus-mediated gene transfer of hu-
man b2AR rescued these defects. Consistent effects were
evoked in vitro both upon b2AR knockdown and pharmacologic
treatment. Interestingly, with aging, wild-type (b2AR
+/+) littermates
developed impaired insulin secretion and glucose tolerance. More-
over, islets from 20-month-old b2AR
+/+ mice exhibited reduced
density of b2AR compared with those from younger animals, par-
alleled by decreased levels of PPARg, PDX-1, and GLUT2. Over-
expression of b2AR in aged mice rescued glucose intolerance and
insulin release both in vivo and ex vivo, restoring PPARg/PDX-1/
GLUT2 levels. Our data indicate that reduced b2AR expression
contributes to the age-related decline of glucose tolerance in
mice. Diabetes 61:692–701, 2012
Impairment of glucose metabolism with age repre-sents a major determinant of type 2 diabetes epi-demics within the elderly population. The molecularmechanisms underlying these changes have not been
fully elucidated and are likely attributable to multiple
causes (1,2). Aging per se is associated with a continuous
decrease in basal insulin release (3). The size of this effect
is sufﬁcient to increase the likelihood of developing ab-
normalities in glucose tolerance and even overt diabetes
(2,4). The consequence of aging on glucose tolerance
occurs in different species, having been identiﬁed in rats
(5,6) as well as in humans (4,7,8). However, why insulin
secretion deteriorates with aging remains a moot point.
The noradrenergic system provides ﬁne-tuning to the
endocrine pancreas activity through the function of a- and
b-adrenergic receptors (ARs) (9,10). The reciprocal regu-
lation exerted by insulin and the adrenergic system has
been well documented through a large number of studies
(11–13). More recent evidence shows that mice with si-
multaneous deletion of the three known genes encoding
the bARs (b1, b2, and b3) present a phenotype character-
ized by impaired glucose tolerance (14). Studies with b2AR
agonists further suggest that the b2AR may play an im-
portant role in regulating insulin secretion (15). In addition,
different human polymorphisms in the b2AR gene have been
associated with higher fasting insulin levels (16). Never-
theless, the impact of the b2AR subtype on glucose toler-
ance and insulin secretion is still unclear.
Similar to glucose tolerance, bAR function and respon-
siveness deteriorate with aging (17–20), but the precise
mechanisms involved are unknown. However, current evi-
dence indicates that aging may downregulate bAR signaling,
b2AR in particular, by decreasing the expression of molecular
components of the adrenergic signaling machinery (21–24).
We have therefore hypothesized that age-dependent alter-
ations in bAR function impair glucose-regulated insulin
release by the pancreatic b-cells and may contribute to
deterioration of glucose tolerance. To test this hypothesis,
we explored the consequences of b2AR knockout on insulin
secretion in mice and investigated the signiﬁcance of the
age-related changes in b2AR function with regard to glucose
tolerance.
RESEARCH DESIGN AND METHODS
In vivo studies. We studied male mice with a homozygous deletion of the
b2AR gene (b2AR
2/2) and backcrossed .12 generations onto C57Bl/6N
background. Founders were provided by Brian Kobilka (Stanford University,
Stanford, CA) (25). Wild-type littermates (b2AR
+/+) were used as controls. The
animals were housed in a temperature-controlled (22°C) room with a 12-h
light/dark cycle in accordance with the Guide for the Care and Use of Labo-
ratory Animals published by the National Institutes of Health (NIH publica-
tion no. 85-23, revised 1996), and experiments were approved by the ethics
committee of the Federico II University. Mice were killed by cervical dislo-
cation. Pancreata were excised and collected rapidly after mice were killed.
Samples were weighted, ﬁxed by immersion in 4% paraformaldehyde for
histology, homogenized for determination of total insulin content, or snap-
frozen in liquid nitrogen and stored at –80°C for subsequent analyses. For
determination of insulin or glucagon content, pancreatic tissue was homog-
enized in acid ethanol and extracted at 4°C overnight. The acidic extracts
were dried by vacuum, reconstituted, and subjected to insulin and glucagon
measurements.
Glucose tolerance test and assessment of insulin secretion. Glucose
tolerance test (GTT) was performed as previously described (9,26). Brieﬂy,
mice were fasted overnight and then injected with glucose (2 g/kg i.p.). Blood
glucose was measured by tail bleeding (Glucose Analyzer II; Beckman Coulter,
Brea, CA) at indicated time points. The assessment of insulin secretion before
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and during glucose challenge was performed as previously described (9,27).
Blood from the mandibular vein of overnight-fasted mice was collected at the
indicated time for serum insulin assessment. The evaluation of glucagon se-
cretion was performed by collecting blood from the mandibular vein of random-
fed mice before and after injection of insulin (0.75 IU/kg i.p.). Serum insulin and
plasma glucagon were assayed by radioimmunoassay (Millipore, Billerica, MA).
Histological analysis. Immunohistochemistry was carried out on parafﬁn
sections using the H38 rabbit insulin antibody or the N-17 goat glucagon anti-
body (1:200 dilution; both from Santa Cruz Biotechnology, Santa Cruz, CA).
Goat anti-rabbit serum coupledwith peroxidase (Immunotech,Marseille, France)
was used as secondary antibody. After primary antibody exposure, slides
were incubated with biotinylated anti-rabbit or anti-goat IgG and peroxidase-
labeled streptavidin (Dako Corporation). All reactions were revealed with
diaminobenzidine. Sections were counterstained with hematoxylin and
mounted (28,29).
Ex vivo studies
Isolation of mouse pancreatic islets. Islets of Langerhans were isolated by
collagenase digestion (26,30). In brief, mice were killed as described above,
the fur was soaked with ethanol, and the abdomen was opened to locate and
excise the pancreas. Digestion was completed with collagenase P (Roche
Applied Sciences, Penzberg, Germany) in a shaking water bath (37°C) for 5–8
min. The digested pancreas was treated with DNase I (New England BioLabs,
Ipswich, MA). The islets were hand-picked under a stereomicroscope using a
syringe with a 25-gauge needle and cultured at 37°C with 95% air and 5% CO2
in complete RPMI-1640 supplemented with 5% heat-inactivated FBS, 1 mmol/L
sodium pyruvate, 50 mmol/L 2-mercaptoethanol, 2 mmol/L glutamine, 10 mmol/L
HEPES, 100 units/mL penicillin, and 100 mg/mL streptomycin (all from Sigma-
Aldrich, Saint Louis, MO) as previously described (31,32).
Evaluation of insulin secretion. Isolated islets were preincubated at 37°C
for 30 min in Krebs-Ringer bicarbonate buffer (120 mmol/L NaCl, 4.7 mmol/L
KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 2.4 mmol/L CaCl2, and 20 mmol/L
NaHCO3) supplemented with 10 mmol/L HEPES and 0.2% BSA and gassed
with a mixture of 95% O2 and 5% CO2 containing 2 mmol/L glucose. Twenty
size-matched islets collected in each tube were incubated for 1 h in a 37°C
water bath with 500 mL Krebs-Ringer bicarbonate buffer medium containing
2.8 mmol/L glucose, 16.7 mmol glucose, or 2.8 mmol/L glucose plus 33 mmol/L
KCl. Islets were then pelleted by centrifugation (9,000g, 2 min, 4°C), and
supernatants were collected for insulin secretion. Insulin concentrations were
determined using radioimmunoassay (31).
Adenovirus-mediated reinstallation of b2AR in vivo and ex vivo.
Twenty-month-old b2AR
+/+ mice were anesthetized by isoﬂurane (4%) inha-
lation and maintained by mask ventilation (isoﬂurane 1.8%) (28). After lapa-
rotomy, we identiﬁed and mobilized the distal pancreas and we performed two
injections (50 mL each) of adenovirus (7 3 1010 plaque-forming units [pfu]/
mouse) using a 30-gauge needle. Given the high homology between the human
and mouse b2AR (33) and the validated use of the adenoviruses expressing the
human b2AR (Adb2AR) for in vivo gene transfer (34–36), we used the human
Adb2AR or, as control, an empty expression cassette derived from pcDNA3.2/
V5/GW/D-TOPO (AdEmpty), kindly provided by Walter J. Koch, Jefferson
University (Philadelphia, PA). Finally, abdominal incision was quickly closed
in layers using 3–0 silk suture, and animals were observed and monitored until
recovery. Isolated islets were infected (12 3 104 pfu/islet) with Adb2AR or
AdEmpty. After 3 h incubation with the adenoviruses, pancreatic islets were
incubated with fresh medium and under normoxic conditions (95% air, 5%
CO2) at 37°C for 24 h.
In vitro studies. The INS-1E b-cells (provided by P. Maechler, University of
Geneva, Geneva, Switzerland), derived and selected from the parental rat
insulinoma INS-1 b-cell line, were maintained in monolayer culture in RPMI-
1640 medium as described above for the ex vivo experiments. For the insulin
secretion assays, cells were seeded at a density of 53 105 cells/cm2 for at least
96 h before use (31). Transient transfection of the PPARg cDNA and control
empty plasmid was performed using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) (37). We also tested the effects of the speciﬁc pharmacological b2AR
antagonist ICI 118.551 (0.1 mmol/L) or agonist (1 mmol/L fenoterol) (both from
Sigma-Aldrich) (36).
Short hairpin RNA design, generation, and transfection and radioligand-
binding assay. Stealth short hairpin (sh)RNA oligoribonucleotides against
b2AR and scramble were designed (sequences and efﬁciency shown in Sup-
plementary Table 1 and Supplementary Fig. 2, respectively) and then syn-
thesized by Invitrogen. The shRNA hairpin conﬁguration is cleaved by the
cellular machinery into small interfering RNA, which is then bound to the
RNA-induced silencing complex. This complex binds to and cleaves mRNAs
that match the small interfering RNA that is bound to it. We transfected INS-1E
b-cells with 100 nmol/L sh-b2AR RNA or sh-scramble RNA using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. Assays were
performed at least 3 days after shRNA transfection. Membrane fractions
from pancreatic tissue, isolated islets, and INS-1E b-cells were used for
radioligand-binding studies to assess the density of ARs as previously de-
scribed and validated (35,36,38,39).
Real-time RT-PCR analysis. Total cellular RNA was isolated from INS-1E
b-cells, isolated islets, and pancreatic tissue samples with the RNeasy kit (Qiagen,
Germantown, MD), according to the manufacturer’s instructions, as previously
described (31,40). PCRs were analyzed using SYBR Green mix (Invitrogen).
Reactions were performed in triplicate using Platinum SYBR Green qPCR
Super-UDG by means of an iCycler IQ multicolor Real Time PCR Detection
system (Bio-Rad, Hercules, CA). Cyclophilin was used as an internal standard.
Primer sequences are reported in Supplementary Table 2.
Immunoblotting. Immunoblot analysis was performed as previously de-
scribed (31,37). Blots were probed with mouse monoclonal antibodies against
adenylate cyclase type VI (AC-VI) (Abcam, Cambridge, MA), pancreatic and
duodenal homeobox (PDX)-1, GLUT2, peroxisome proliferator–activated re-
ceptor (PPAR)g, G-protein–coupled receptor (GRK)2, G protein as (Gas),
clathrin heavy chain, and actin (Santa Cruz Biotechnology). Experiments were
performed in triplicate to ensure reproducibility. Membrane extracts were
obtained as previously described (29,38). Data are presented as arbitrary units
using actin as internal control (clathrin heavy chain for membrane extracts) as
indicated.
Measurement of cAMP production in vitro and ex vivo. Intracellular
content of cAMP was determined using a cAMP 125I-scintillation proximity
assay (GE Healthcare, Piscataway, NJ) according to the manufacturer’s in-
structions. Brieﬂy, we used 20 size-matched islets (for the ex vivo assays) and
4,000 cells/well INS-1E (for the in vitro assays). Islets and b-cells were washed
once and preincubated at 37°C in HEPES-buffered Krebs-Ringer solution con-
taining 1 mmol/L glucose and 0.5 mmol/L isobutylmethylxanthine (a phospho-
diesterase inhibitor) for 1 h and incubated for another 15 min in the same buffer
with or without 100 mmol/L forskolin (MP Biomedicals, Solon, OH), 3 mmol/L
NaF (Thermo Fisher Scientiﬁc, Pittsburgh, PA), or 1 mmol/L isoproterenol
(Tocris Bioscience, Ellisville, MO). The reaction was stopped by addition of 50
mmol/L HCl and neutralized with NaOH. The cAMP levels were normalized to
the protein concentration.
Statistical analysis. All data are presented as means 6 SE. Statistical dif-
ferences were determined by one-way or two-way ANOVA as appropriate, and
Bonferroni post hoc testing was performed when applicable. A P value ,0.05
was considered signiﬁcant. Statistical analysis was performed using GraphPad
Prism (version 5.01; GraphPad Software Inc., San Diego, CA).
RESULTS
Metabolic phenotype of b2AR
2/2 mouse. To investigate
in vivo the relevance of the b2AR gene in the regulation of
insulin secretion, we compared the metabolic phenotype
of adult (6 months old) b2AR
2/2 and b2AR
+/+ mice. Blood
glucose was signiﬁcantly higher in the null mice compared
with that in their wild-type littermates both upon fasting
and under random feeding conditions (Table 1). In addition,
their fasting serum insulin levels were signiﬁcantly reduced
(Table 1). Upon glucose loading (GTT), the b2AR
2/2 mice
displayed a marked reduction in glucose tolerance (Fig. 1A
and B). In b2AR
+/+ mice, we observed a threefold increase
in insulin secretion 3 min after intraperitoneal glucose in-
jection, presumably corresponding with the peak of ﬁrst-
phase insulin release. This was followed by a decrease at 10
TABLE 1
Metabolic characteristics of adult (6 months old) wild-type and
knockout mice
b2AR
+/+ b2AR
2/2
n 15 14
Body weight (g) 29.6 6 1.1 28.2 6 0.7
Food intake (g/day) 3.1 6 0.6 3.1 6 0.8
Water intake (mL/day) 5.8 6 0.6 6.3 6 0.9*
Random-fed blood glucose (mg/dL) 170.1 6 12.3 198.4 6 11.1*
Fasting blood glucose (mg/dL) 75.7 6 8.2 135.3 6 11.5*
Fasting serum insulin (ng/mL) 0.41 6 0.03 0.30 6 0.07*
Data are means 6 SE unless otherwise indicated. *P , 0.05 vs.
b2AR
+/+.
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FIG. 1. Metabolic proﬁle of b2AR
2/2mice. Six-month-old b2AR
2/2mice and their wild-type littermates (b2AR
+/+) were fasted for 16 h and subjected
to intraperitoneal glucose loading (2 g/kg body weight). Blood glucose (A and B) and serum insulin (C and D) were monitored for 120 min after
glucose administration (n = 14–18 animals per group). b2AR
2/2 mice displayed glucose intolerance (A) and impaired insulin secretion (C). We
calculated the AUC from glucose (B) and insulin excursion (D) curves. Peak insulin–to–peak glucose ratio (E) represents b-cell function, as better
described in RESEARCH DESIGN AND METHODS. Bars represent means 6 SE. *P < 0.05 vs. b2AR
+/+, Bonferroni post hoc test. AUC, area under the curve.
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min and then a gradual increase over 30 min that may in-
dicate a second-phase response (27,41).
In b2AR
2/2 mice, the early phase of insulin secretory
response to glucose was reduced by more than twofold. The
late response was also signiﬁcantly impaired in the b2AR
2/2
compared with b2AR
+/+ mice (Fig. 1C and D). The peak
insulin–to–peak glucose ratio was also decreased (Fig. 1E),
further indicating impaired insulin response to hyperglyce-
mia in the null mice.
To investigate whether the alterations in glucose toler-
ance identiﬁed in the b2AR
2/2 mice were contributed by
deranged glucagon release, we further measured blood
glucose and plasma glucagon levels 30 min after insulin
administration. Indeed, insulin administration determines a
fall in blood glucose and a counterregulatory rise in plasma
glucagon (2,30). However, b2AR
2/2 and b2AR
+/+ mice ex-
hibited comparable glucose and glucagon responses to
insulin administration (Supplementary Fig. 1A and B).
Pancreatic islet histology also did not show any signiﬁcant
difference in these mice (Fig. 2A), similar to total insulin and
glucagon pancreatic content (Fig. 2B and C).
We then posed the further question of whether the re-
duced glucose insulin secretion observed in the b2AR
2/2
mice in vivo may represent the direct consequence of the
b2AR
2/2 lack in the b-cells or whether it is indirectly me-
diated by other regulatory factors. To answer this question,
we analyzed glucose effect on islets isolated from the null
mice. As shown in Fig. 2D, these islets responded poorly to
increased glucose concentration in the culture medium
compared with the islets from their wild-type littermates but
were fully responsive to KCl depolarization.
Islets and b-cell proﬁling after b2AR deletion. To gain
further insight into the mechanism leading to impaired in-
sulin secretion in mice lacking b2AR, we proﬁled the ex-
pression of different genes relevant to b-cell regulation by
real-time RT-PCR of islet mRNA. As shown in Fig. 3A and B,
mRNA levels of both PDX-1 and GLUT2, two major genes
involved in b-cell function, were decreased in islets from
b2AR
2/2 mice by 75 and 60%, respectively. Also, mRNA
levels of the PDX-1/GLUT2 upstream regulator PPARg
were decreased by 54% compared with islets from wild-
type mice (Fig. 3C). Reliable results were obtained in
FIG. 2. Comparison of b2AR
+/+ and b2AR
2/2 pancreatic islets. Immunoistochemical analysis (A) of the islets was carried out on parafﬁn sections
using insulin (left panel) or glucagon (right panel) antibodies. Microphotographs are representative of images obtained from pancreas sections
of ﬁve 6-month-old b2AR
+/+ (upper panel) or b2AR
2/2 (lower panel) mice. Insulin (B) and glucagon (C) content in isolated islets from b2AR
+/+
(n = 10) or b2AR
2/2 (n = 13) mice. Insulin secretion in response to basal (2.8 mmol/L) or high (16.7 mmol/L) glucose concentration and to KCl (33
mmol/L) was measured in isolated islets from b2AR
+/+ (□) and b2AR
2/2 (■) mice (D). Bars represent means 6 SE of data from 10 mice per group.
*P < 0.05 vs. b2AR
+/+, Bonferroni post hoc test. (See also Supplementary Fig. 1.) (A high-quality digital representation of this ﬁgure is available in
the online issue.)
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immunoblotting experiments (Fig. 3D and E). PDX-1 and
GLUT2 mRNAs were also reduced to a similar extent in
total pancreatic tissue from the b2AR
2/2 mice (data not
shown).
We then sought to demonstrate whether these abnor-
malities in gene expression were directly caused by b2AR
silencing. To pursue this objective, we silenced with a
speciﬁc shRNA (Supplementary Fig. 2) the b2AR gene in
the glucose-responsive INS-1E b-cell line (INS-1Eshb2AR)
(Fig. 4A and B). As shown in Fig. 4C, this speciﬁc knock-
down impaired glucose-induced insulin secretion by 58% in
these cells. A similarly sized effect was achieved by treat-
ment with the speciﬁc b2AR antagonist ICI, while the b2AR
agonist fenoterol showed an opposite action (Supplemen-
tary Fig. 3A). Consistent with our ex vivo results, the INS-
1Eshb2AR displayed a reduction in PDX-1, GLUT2, and
PPARg mRNA (Fig. 4D–F) and protein levels (Fig. 4G and
H). Interestingly, transient transfection of a PPARg cDNA in
INS-1Eshb2AR b-cells increased glucose-induced insulin se-
cretion compared with the wild-type INS1-E control b-cells
(Fig. 4C). In addition, overexpression of PPARg prevented
the downregulation of both PDX-1 and GLUT2 occurring in
the INS-1Eshb2AR b-cells (Fig. 4D–H). Consistently, treatment
of INS-1E b-cells with ICI decreased PDX-1 and GLUT2
mRNA and protein levels, while PPARg overexpression
completely prevented the effect of ICI (Supplementary Fig.
3B–D), suggesting that b2AR controls insulin secretion
through a PPARg/PDX-1–mediated mechanism.
To better deﬁne the b2AR downstream mechanism lead-
ing to PPARg activation, we assessed the cAMP levels in
these cells, observing an impaired production of cAMP in
INS-1Eshb2AR b-cells both in basal condition and after stim-
ulation with the bAR agonist isoproterenol (Supplementary
Fig. 4A). Accordingly, to rule out possible involvement of
other components of b2AR signaling machinery, we assessed
the protein level of AC-VI, GRK2, and Gas, and we found
no signiﬁcant difference (Supplementary Fig. 4B and C).
Parallel results were obtained in ex vivo experiments,
performed to investigate the possible age-related alter-
ations in the b2AR transduction pathway, comparing
pancreatic islets isolated from adult (6 months old) and
old (20 months old) b2AR
+/+ mice (Supplementary Fig. 4D
and E).
b2AR overexpression rescued the age-related impairment
in insulin release. Based on radioligand binding and real-
time RT-PCR analysis, the expression of both b2AR protein
and mRNA was signiﬁcantly decreased in islets from aged
(20 months old) b2AR
+/+ mice compared with those isolated
from adult (6 months old) mice (Fig. 5A and B). PDX-1,
GLUT2, and PPARg expression (both in terms of mRNA
and protein level) was also reduced, and insulin release
in response to glucose, though not that evoked by KCl de-
polarization, was impaired in islets from the aged mice (Fig.
5C–H), suggesting that the reduced b2AR density constrains
islet glucose response in these animals. To prove this hy-
pothesis, we used an adenoviral construct driving over-
expression of human b2AR in mouse islets. Interestingly,
infection of islets isolated from wild-type old mice with this
construct induced a twofold increase in b2AR expression
(Fig. 5A and B) and returned glucose-induced insulin secre-
tion to levels comparable with those of islets from 6-month-
old mice (Fig. 5C) accompanied by restored expression of
PDX-1, GLUT2, and PPARg (Fig. 5D–H).
In the in vivo setup, 20-month-old b2AR
+/+ mice exhibited
a signiﬁcant reduction in fasting serum insulin levels
(Table 2) accompanied by impaired glucose tolerance and
FIG. 3. Gene expression proﬁle in isolated Langerhans islets from b2AR
+/+ and b2AR
2/2mice. The abundance of mRNAs for PDX-1 (A), GLUT2 (B),
and PPARg (C) was determined by real-time RT-PCR analysis of total RNA, using cyclophilin as internal standard. The mRNA levels in b2AR
2/2 mice
are relative to those in control animals. Each bar represents means6 SE of four independent experiments in each of which reactions were performed
in triplicate using the pooled total RNAs from ﬁve mice/genotype. Proteins from aWestern blot representative of three independent experiments were
quantiﬁed by densitometry (D and E). *P < 0.05 vs. b2AR
+/+, Bonferroni post hoc test. AU, arbitrary units.
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insulin response upon GTT (Fig. 6A–E). We have therefore
designed a gene therapy protocol aimed to prove that
these abnormalities can be corrected by restoring b2AR
density. Accordingly, we infected the pancreas of aged
mice by Adb2AR injection. This injection effectively res-
cued b2AR expression in the pancreatic tissue, returning it
to levels comparable with those of 6-month-old mice (Sup-
plementary Fig. 5A and B), and restored the expression of
PDX-1, GLUT2, and PPARg (Supplementary Fig. 5C–E).
Injections in the distal pancreas did not induce b2AR ex-
pression in other tissues, such as the liver (Supplementary
Fig. 6A and B) or the skeletal muscle (Supplementary Fig.
6C and D).
These effects were paralleled by signiﬁcant improve-
ment in glucose tolerance and insulin secretion during
GTT (Fig. 6A–E). Fasting insulin levels also increased,
reaching values similar to those measured in 6-month-old
mice (Table 2), further underlining the relevance of b2AR
function in enabling adequate pancreatic b-cell response
to hyperglycemia.
DISCUSSION
In the present work, we provide evidence that b2AR gene
deletion in mice causes reduction of glucose-stimulated
insulin release by pancreatic b-cells. This phenotype is
reminiscent of that observed in mice with targeted b-cell
disruption of the Gas gene (30). In these mice, however,
the impairment of Gas prevented response to multiple Gas-
related receptors, causing a severe phenotype, with gross
abnormalities in pancreatic islets. Interestingly, in islets
from b2AR
2/2 mice, PPARg expression was reduced by
50%, leading to repression of the PPARg downstream mol-
ecules PDX-1 and GLUT2, two key effectors of b-cell
function (26,42,43). This downregulation resulted in a clear
impairment in insulin release, though islet architecture and
insulin content were not affected by the b2AR gene de-
letion.
Rosen et al. (44) showed that islets from mice with
targeted elimination of PPARg in b-cells were approxi-
mately twice as large as those from control mice. Thus, we
can speculate that in our model the 50% reduction in
FIG. 4. b2AR levels, glucose-stimulated insulin secretion, and gene expression proﬁle in silenced INS-1E b-cells. Treatment with a speciﬁc b2AR-
shRNA signiﬁcantly decreased the density (by 73.7% [A]) and mRNA levels (by 59.1% [B]) of b2AR in INS-1E b-cells. b2AR-shRNA inhibited the
insulin secretory response to 16.7 mmol/L glucose, which was rescued by the overexpression of PPARg (C). KCl-induced insulin release (C) was
not signiﬁcantly different among the studied groups. b2AR-shRNA also determined a signiﬁcant reduction in mRNA level of PDX-1 (D), GLUT2 (E),
and PPARg (F) that was prevented by the overexpression of PPARg. Bars represent means6 SE from four to ﬁve independent experiments in each
of which reactions were performed in triplicate ( , control, i.e. untreated INS-1E b-cells; , sh-scramble; , sh-scramble+empty vector; ,
sh-b2AR; , sh-b2AR+PPARg; *P < 0.05 vs. control, Bonferroni post hoc test; basal is glucose 2.8 mmol/L. Equal amount of proteins from three
independent experiments was analyzed by Western blotting and quantiﬁed by densitometry (G and H ). *P < 0.05 vs. sh-scramble. AU, arbitrary
units. (See also Supplementary Figs. 2–4.)
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PPARg levels is sufﬁcient to restrain b-cell function with-
out altering islet mass.
The mechanistic signiﬁcance of b2AR gene knockout
was further sustained by in vitro studies in the INS-1E
pancreatic b-cells, showing that the silencing of the b2AR
as well as the pharmacological treatment with a speciﬁc
b2AR antagonist impaired glucose response and down-
regulated PPARg expression, reducing both PDX-1 and
GLUT2 levels. No alteration of aARs was observed instead
(data not shown). In addition, treatment with the b2AR
agonist fenoterol activated PPARg/PDX-1/GLUT2 signal-
ing, indicating that, at least in part, b2AR controls insulin
secretion through this pathway. Indeed, in this study we
show that exogenous PPARg expression in INS-1E b-cells
silenced for b2AR led to recovery of PDX-1/GLUT2 levels
and glucose-stimulated insulin secretion. This ﬁnding is
supported by recent evidence that directly relates b2AR to
PPARg (42,45–47), a key element in the process of insulin
FIG. 5. b2AR ex vivo infection rescued age-dependent impairment of b-cell function. Density (A) and mRNA levels (B) of b2AR were evaluated on
cell membranes of islets isolated from b2AR
+/+ mice. Insulin release (C) was determined upon exposure to the indicated concentration of glucose or
KCl as described in RESEARCH DESIGN AND METHODS. mRNA levels of PDX-1 (D), GLUT2 (E), and PPARg (F) were determined by real-time RT-PCR using
the pooled total RNAs from ﬁve mice/group with cyclophilin as internal standard. Each bar represents means6 SE of ﬁve independent experiments in
each of which reactions were performed in triplicate. Islets isolated from b2AR
+/+ mice were solubilized and aliquots of the lysates were blotted with
PDX-1, GLUT2, and PPARg antibodies. Actin was used as loading control. The autoradiographs shown (G) are representative of three independent
experiments, which are quantiﬁed in H. , age 6 months (mos); , 20 months; , 20 months AdEmpty; , 20 months Adb2AR. *P < 0.05 vs.
b2AR
+/+ 6 months, Bonferroni post hoc test.
TABLE 2
Metabolic effects of b2AR overexpression in aged (20 months old) b2AR
+/+ mice
20 months old 6 months old
Untreated AdEmpty Adb2AR Untreated
n 10 6 8 15
Body weight (g) 38.4 6 1.7* 38.1 6 2.4* 38.6 6 2.1* 29.6 6 1.1
Food intake (g/day) 4.0 6 1.1* 4.2 6 1.8* 3.9 6 1.5* 3.1 6 0.6
Water intake (mL/day) 6.8 6 1.2* 6.9 6 1.7* 6.6 6 1.8* 5.8 6 0.6
Random-fed blood glucose (mg/dL) 176.5 6 8.6 178.4 6 12.7 173.2 6 10.4 170.1 6 12.3
Fasting blood glucose (mg/dL) 84.2 6 10.4 83.6 6 11.9 77.7 6 11.7 75.7 6 8.2
Fasting serum insulin (ng/mL) 0.32 6 0.04* 0.33 6 0.05* 0.42 6 0.1 0.41 6 0.03
Data are means 6 SE unless otherwise indicated. *P , 0.05 vs. adult (6 months old) b2AR
+/+ mice.
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FIG. 6. Adenoviral vector-mediated b2AR gene transfer in the mouse pancreas rescued age-related reduction in glucose tolerance. Blood glucose
levels (A) and serum insulin (C) after 120 min of glucose administration (n = 14–18 animals per group). We calculated the AUC from glucose (B)
and insulin excursion (D) curves. Twenty-month-old b2AR
+/+ mice showed glucose intolerance (A and B), impaired insulin secretion (C and D), and
also an impairment in b-cell function, evaluated measuring the peak insulin–to–peak glucose ratio (E). All of these parameters were restored after
Adb2AR in vivo infection. *P < 0.05 vs. b2AR
+/+ at 6 months (mos) of age, Bonferroni post hoc test. (See also Supplementary Figs. 5 and 6.)
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secretion that has also recently been investigated in aging
(43,48). Our results are consistent with these observations,
sustaining also the hypothesis that cAMP levels could act
as a connecting link through which b2AR signaling leads to
activation of PPARg (49,50). Moreover, the cAMP assays,
performed both in INS-1Eshb2AR pancreatic b-cells and in
islets isolated from aged mice, showed an impairment in
basal conditions and after stimulation with isoproterenol,
while the responses to NaF and forskolin were not affected.
Also, Gas and AC-VI protein levels were not signiﬁcantly
different among the explored settings. This combination of
events is usually observed in models of b2AR gene deletion
or impaired b2AR signaling (18,34).
Whether and to what extent b2AR gene knockout in liver
and peripheral tissues affects glucose homeostasis in the
b2AR
2/2 mice remain to be conclusively addressed. In-
deed, variations at the b2AR locus have also been reported
to associate with insulin resistance in type 2 diabetic patients
(16). However, as shown in this work, the impaired glu-
cose tolerance of b2AR
2/2mice is likely contributed by the
defective b-cell function, as indicated by the major effect
of b2AR lack on glucose-evoked insulin secretion.
In humans, glucose tolerance declines with age, result-
ing in a high prevalence of type 2 diabetes and impaired
glucose tolerance in the elderly population (2,8). How, at
the individual level, glucose tolerance declines remains
unclear, but it is likely determined by multiple factors in-
cluding diminished insulin secretion (3,7). In rat models
and in humans, a progressive decline in b-cell activity with
age has been documented (4,6). In the present work, we
show that the same occurs in the C57Bl/6N mouse and is
paralleled by the development of abnormal glucose toler-
ance. Similar to previous ﬁndings in several human tissues
(18–21,24), our results show that these changes are ac-
companied by reduced b2AR levels in mouse pancreatic
islets. The decreased b2AR density in islets from aged mice
recapitulates the mechanisms leading to the insulin se-
cretory defect occurring in b2AR-null mice, indicating that
it may contribute to the age-related impairment in glucose
tolerance. Indeed, both in vivo and ex vivo experiments of
b2AR gene transfer revealed that recovery of normal b2AR
levels rescued insulin release and glucose tolerance in
aged mice. Thus, in the mouse model progressive decline
of islet b2AR density appears to contribute to the reduction
in glucose tolerance that accompanies aging. Whether the
same also occurs in humans needs to be clariﬁed and is
currently under investigation in our laboratory.
In conclusion, we have shown that b2AR physiologically
regulates pancreatic b-cell insulin secretion by modulating
PPARg/PDX-1/GLUT2 function. Reduced b2AR expression
contributes to the age-dependent deterioration of glucose
tolerance.
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